Key Takeaways for Atlanta Dentists
- Most 2026 Atlanta DSO deals deliver 60%–80% cash at close, with the rest split between rollover equity and performance-based earnouts.
- Multi-doctor practices with $2M–$4M revenue often receive higher EBITDA multiples, around 6.0x–8.0x, than solo GPs.
- A competitive, multi-buyer process can be one of the most reliable ways to capture a 30%–50% DSO premium over private-buyer values.
- LOI terms such as long exclusivity windows, broad non-competes, and uncapped indemnification can reduce seller proceeds and usually deserve pushback.
- McLerran & Associates runs a structured auction-style process that consistently delivers roughly 30% higher valuations; schedule your free, confidential discovery call today to see what your Atlanta practice could be worth.
How Atlanta’s Growth Shapes DSO Deal Terms
Atlanta’s growth trajectory directly influences practice valuations. The 11-county metro added 53,690 residents between April 2025 and April 2026, bringing total population to 5.3 million. That steady inflow expands patient pools and strengthens the demographic story DSO buyers use to support premium pricing. Multi-location practices that can spread new patient volume across several sites often benefit the most.
The scale premium shows up clearly in pricing. Solo GP practices in the $1.2M–$2M revenue range often transact at lower multiples. Multi-doctor practices with $2M–$4M revenue can command 6.0x–8.0x EBITDA, which creates a meaningful gap in value. EBITDA, or Earnings Before Interest, Taxes, Depreciation, and Amortization, is the profitability metric DSOs use to set purchase prices. A higher EBITDA multiple simply means more dollars paid for each dollar of practice profit.
How 2026 Atlanta DSO Deals Pay Sellers
Deal structure can matter as much as the top-line price. A typical 2026 DSO transaction in Atlanta delivers roughly 60%–80% cash at close, 15%–40% rollover equity, and 5%–15% in earnouts tied to EBITDA or production targets over 12 to 36 months. Two equity structures appear most often:
- JV (Joint Venture) equity: The DSO acquires a majority stake, typically 51%–80%, while the selling dentist keeps 20%–49% at the practice level. The seller receives ongoing profit distributions after a management fee. This structure provides current income but limits upside to the performance of that specific practice.
- HoldCo (Holding-company) equity: The DSO acquires 100% of the practice. The seller receives 65%–90% cash at close plus 10%–35% equity in the DSO’s parent company. There are no regular distributions, and this equity is usually illiquid for 5–7 years. If the platform later sells at a higher valuation multiple than the entry multiple, often called the “second bite of the apple,” the upside can be significant.
Clinical autonomy under either structure is typically protected by the MSO/PC legal split. Post-close employment agreements usually run 2–5 years. Sellers can treat the employment term as a point of negotiation rather than a fixed rule.
Why Atlanta Sellers Benefit from Real Competition
Talking with multiple buyers before signing anything can be one of the most important steps for an Atlanta practice owner. DSOs often pay a 30%–50% premium over private individual-buyer transactions when the practice fits their platform. That premium usually appears only when buyers compete directly. An owner who approaches a single DSO gives up competitive tension and negotiates from a weaker position.
The spread between the best and middle-tier offers on the same practice has widened in 2026. The difference between a well-run competitive process and a single-offer negotiation can reach hundreds of thousands of dollars.
Capturing that spread usually requires a structured approach that forces buyers to compete on similar terms. McLerran & Associates runs a structured, auction-style bid process that typically lasts 45–60 days and generates around 10 offers from a vetted pool of well-qualified buyers. Poorly run DSOs are removed before the process begins, so owners see only credible, well-capitalized partners. The firm works both doctor-to-doctor and DSO paths in roughly equal measure, which gives each client a true side-by-side comparison instead of a push toward one lane. The result: clients capture the premium described earlier, roughly 30% above what owners often achieve on their own.
Owners who are not ready to sell but want clarity on value can still prepare. Join the McLerran M&A Summit on October 29–30, 2026, a dental-only event for undecided owners, featuring expert panels, one-on-one CPA sessions, and a complimentary $2,500 practice valuation.
Key LOI Terms and Buyer Fit for Atlanta DSOs
A letter of intent (LOI) sets the main terms of a DSO acquisition before attorneys draft full contracts. Most LOIs are non-binding on price but binding on exclusivity. Once signed, the seller usually cannot talk to other buyers for a set period. Several common LOI terms in Atlanta can disadvantage sellers who sign without careful review.
These red-flag LOI terms can shift risk and economics toward the buyer and deserve close attention:
- Long exclusivity windows: DSO LOIs often require exclusivity periods of 60–120 days, during which the seller cannot solicit or consider competing offers. Shorter windows or staged exclusivity tied to diligence milestones are generally more seller-friendly.
- Broad non-competes: Non-compete clauses frequently start at a 25+ mile radius and 7+ years. Industry norms often allow negotiation down to 5–15 miles and 2–3 years, with carve-outs for teaching and consulting.
- Aggressive EBITDA adjustments: Buyers apply valuation multiples to a normalized EBITDA figure and may push that figure down during diligence. The LOI should spell out exactly how EBITDA will be calculated and which add-backs are accepted.
- Uncapped indemnification: A seller-friendly structure usually caps indemnification at a percentage of the purchase price with a clear survival period. Unlimited post-close liability can expose the seller to open-ended risk.
- Vague earnout metrics: Earnouts work best when baseline performance metrics are clearly defined in the LOI. Ambiguous or unrealistic targets can prevent a meaningful portion of proceeds from ever being paid.
Before signing any Atlanta LOI, many sellers find value in a simple five-question checklist:
- Is the exclusivity period 60 days or fewer, with clear milestones that can end it early?
- Are the EBITDA definition and all accepted add-backs written clearly in the LOI?
- Is the non-compete reasonable in distance and duration, with carve-outs for non-clinical work?
- Is indemnification capped at a defined percentage of the purchase price with a fixed survival period?
- Are earnout metrics objective, measurable, and tied to factors the seller can influence after closing?
Vetting the buyer can be just as important as reviewing the LOI. Too many DSOs have grown through financial engineering and rapid expansion instead of stable fundamentals. A seller who rolls 20%–35% of proceeds into a weak platform faces real risk of delayed or reduced returns on that equity. Because rollover equity ties the seller’s outcome directly to the platform’s performance, underwriting the buyer’s profitability, growth path, management depth, and recapitalization history becomes part of the transaction, not an optional extra step.
Positioning Your Atlanta Practice for a Strong Outcome
McLerran & Associates has completed approximately 2,000 successful practice sales representing roughly $2 billion in closed transaction volume, with a transaction rate of about 85%–90% compared with an industry norm closer to 35%–40%. That record comes from a process that shapes the EBITDA story from day one. The goal is for the agreed valuation to hold through diligence instead of being pushed down near closing.
The 2027 outlook for Atlanta-area sellers appears cautiously constructive. About 69% of surveyed DSOs expect their private equity sponsors to drive a moderate or high increase in acquisition activity in 2026, and 78% anticipate recapitalizations within the next 12–36 months, which signals that capital is cycling back into new acquisitions. That capital influx can support buyer appetite, but it comes with a tradeoff. DSOs are also becoming more selective, prioritizing provider stability, clinical continuity, and durable financial performance, and they now require minimum 5-year post-close employment terms more often.
For Atlanta owners, the sustained population growth noted earlier and the high-demand, low-supply environment for premium practices create a favorable window. That window tends to stay open for practices with clean financials, integrated operations, and a credible post-close clinical team. The market is shifting toward disciplined expansion that emphasizes profitability and same-store growth at existing locations before new acquisitions. Buyers are paying premiums for practices that fit smoothly into their current platforms.
Schedule a free, confidential discovery call with McLerran & Associates at (512) 900-7989 or visit their contact page to learn what your Atlanta practice could be worth in both private-buyer and DSO markets and which path may support your goals.
Frequently Asked Questions
What cash-at-close percentage is realistic for a $2M Atlanta GP in 2026?
A $2M revenue general practice in Atlanta usually falls into the solo GP scale tier, where cash at close often ranges from 75% to 85% of total consideration. The exact percentage can depend on EBITDA margin, payer mix, provider concentration, and the number of buyers competing. Practices with clean financials, diversified production, and low Medicaid exposure tend to attract stronger cash-at-close offers than those with heavy owner production or reimbursement risk. The remaining consideration is generally split between rollover equity, reinvested into the acquiring platform, and an earnout tied to post-close EBITDA or production over 12–36 months. A competitive process with multiple vetted buyers can be one of the most reliable ways to push cash at close toward the higher end of that range.
How do JV and holding-company equity differ for Atlanta sellers?
JV equity keeps the selling dentist as a minority owner at the practice level, usually 20%–49%, with ongoing profit distributions after the DSO’s management fee. The income floor is higher because distributions start quickly, but upside is limited to that single location. Holding-company equity works differently. The DSO acquires 100% of the practice, and the seller receives a smaller equity stake in the DSO’s parent company instead of the practice. There are no regular distributions, and the equity is typically illiquid for about 5–7 years. The upside ties to the entire platform, so a recapitalization or sale at a higher multiple can increase the value of that equity. Some transactions use a hybrid structure that combines both approaches. The right mix can depend on the seller’s income needs, risk tolerance, and confidence in the DSO’s growth plan.
Which LOI terms should raise red flags in Atlanta deals?
Five LOI terms often deserve close review in Atlanta DSO transactions. Exclusivity periods longer than 60 days can lock the seller out of the market while the buyer moves at its own pace, so shorter windows with milestone-based termination rights can be more protective. Non-compete clauses that cover broad distances and long timeframes are common starting points but are usually negotiable, and many sellers push for narrower scope with carve-outs for teaching, consulting, and expert witness work. Vague EBITDA definitions give buyers room to adjust profitability downward during diligence, which effectively cuts the price after signing, so the calculation method and add-backs should be explicit. Uncapped indemnification exposes the seller to unlimited post-close liability and often should be capped at a defined percentage of the purchase price with a fixed survival period. Earnout metrics that are unclear, tied to factors outside the seller’s control, or measured over very long periods can make it difficult to collect the full amount. A qualified sell-side advisor typically reviews all five areas before any LOI is signed.
Will buyer appetite remain strong into 2027?
The 2027 outlook appears cautiously positive for well-positioned Atlanta practices. Many DSOs surveyed in mid-2026 expected their private equity sponsors to increase acquisition activity, and a large share anticipated recapitalizations within 1–3 years. Both signals suggest that capital is cycling into new deals. Atlanta’s population growth and the structural undersupply of premium practices in the 11-county metro can support continued buyer interest. Buyers, however, are more selective than during the 2019–2021 peak. Practices with significant Medicaid exposure, heavy owner-production concentration, or siloed multi-location operations often face more scrutiny and more conservative offers. Practices with integrated operations, durable financials, a stable clinical team, and a clear continuity plan tend to attract the strongest 2027 buyer appetite. Owners who start preparing now, with a diligence-grade EBITDA review and a structured competitive process, can be better positioned to capture the remaining premiums in the Atlanta market.
The Bottom Line for Atlanta Practice Owners
Atlanta’s population growth, strong demand for premium practices, and the widening gap between top and mid-tier DSO offers all point to a similar conclusion: the sale process can matter as much as the practice itself. An owner who approaches a single buyer, accepts a free valuation, or signs an LOI without careful review may leave meaningful money on the table and may also partner with a buyer who is not the right fit for the next 5 or more years.
McLerran & Associates is a dental-specific sell-side advisor that runs both doctor-to-doctor and DSO paths in roughly equal measure, delivers a diligence-grade EBITDA analysis that can withstand buyer review, and typically generates about 10 vetted offers through a structured auction process with weaker DSOs removed before the first call. The firm’s track record, detailed earlier, reflects a process built around the seller’s outcome rather than buyer convenience.
Schedule a free, confidential discovery call with McLerran & Associates, call (512) 900-7989, email info@dentaltransitions.com, or get in touch through their contact page. Atlanta’s Matt Sutton and the McLerran team can show you what your practice may be worth and what a well-run process can deliver.
